Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
RESEARCH TOOLSreports
Holding COLL?
Track your performance easily
COLL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.16 - $42.29
Previous Close$30
Volume199.40K
Average Volume (3M)397.01K
Market Cap
$978.95M
Enterprise Value$1.71B
Total Cash (Recent Filing)$119.96M
Total Debt (Recent Filing)$874.39M
Price to Earnings (P/E)12.9
Beta0.58
Next Earnings
Feb 20, 2025EPS Estimate
$1.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.32
Shares Outstanding22,300,043
10 Day Avg. Volume623,318
30 Day Avg. Volume397,006
Standard Deviation0.16
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.85
Price to Sales (P/S)1.11
Price to Cash Flow (P/CF)-18.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.86
Enterprise Value/Gross Profit5.25
Enterprise Value/Ebitda5.40
Forecast
1Y Price Target
$42.33Price Target Upside38.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Collegium Pharmaceutical News
PremiumCompany Announcements
Collegium Pharmaceutical Reports Strong Q3 2024 Results
PremiumCompany Announcements
Collegium Pharmaceutical Appoints Vikram Karnani as CEO
PremiumPre-Earnings
Is COLL a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Acquisition And DiversificationThe Ironshore deal diversifies the business from just pain and increases the growth and margin profile of the company.
Financial PerformanceCollegium reported record revenue and adj. EBITDA, and announced the appointment of new CEO, Vikram Karnani, previously head of commercial at Horizon Therapeutics.
Leadership ChangeThe key news of the earnings update is the CEO appointment of Vikram Karnani who comes from Amgen/Horizon with a rare disease commercial background.
Bears Say
Growth PotentialMaintain a Hold rating as more details on the growth potential and profitability of COLL's newly-expanded product portfolio are awaited.
Product StrategyAnother plan will downgrade both products to parity positions.
Sales PerformanceLower than expected sales in both Xtampza and the Nucynta franchise.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $25.16 and its highest was $42.29 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Currently, no data Available
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Feb 20, 2025 which is in 91 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Nov 07, 2024. The company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.591 by $0.019.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is $1.51.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,250,237 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.61 in its last earnings report, beating expectations of $1.591. Following the earnings report the stock price went down -7.347%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Among the largest hedge funds holding Collegium Pharmaceutical’s share is Royce & Associates LLC. It holds Collegium Pharmaceutical’s shares valued at 12M.
---
Collegium Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.33 (38.29% Upside)
$42.33 (38.29% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 33.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.23%
12-Months-Change
Fundamentals
Return on Equity
42.89%
Trailing 12-Months
Asset Growth
38.86%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
---
COLL Company Deck
---
COLL Earnings Call
Q3 2024
0:00 / 0:00
---
COLL Stock 12 Month Forecast
Average Price Target
$42.33
▲(38.29% Upside)
Technical Analysis
Best Analysts Covering COLL
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
-0.97%
reiterated a buy rating 14 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of -0.97% per trade.
---